Skip to Content
MilliporeSigma
All Photos(1)

Documents

SML2310

Sigma-Aldrich

Thiodigalactoside

≥98% (HPLC)

Synonym(s):

Thiodigalactoside, β-D-Galactopyranosyl 1-thio-β-D-galactopyranoside, D-Galactopyranosylthio-β-D-galactopyranoside, TDG, D-Galactopyranosyl-β-D-thiogalactopyranoside

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C12H22O10S
CAS Number:
51555-87-4
Molecular Weight:
358.36
MDL number:
MFCD00057491
UNSPSC Code:
12352200
NACRES:
NA.77

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

H2O: 2 mg/mL, clear

storage temp.

−20°C

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Thiodigalactoside (TDG)is a potent inhibitor of galectin-1 (GAL1) that suppress tumor growth by inhibiting multiple cancer enhancing activities of galectin-1, including immune cell dysregulation, angiogenesis and protection against oxidative stress. Thiodigalactoside reverses galectin-1-induced cisplatin resistance in HCC cells. Thiodigalactoside significantly reduces body weight gain in diet-induced obese rats.

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

S Aggarwal et al.
Oral diseases, 22(5), 445-453 (2016-03-24)
Thiodigalactoside (TDG), a synthetic inhibitor of β-galactoside-binding protein (β-GBP) suppresses tumour growth by inhibiting multiple cancer enhancing activities of β-GBP. Hence, we attempted to understand whether disruption of β-GBP functions and indirect inhibition of Treg cells by TDG affect the
Yu-Chi Su et al.
PloS one, 11(2), e0148408-e0148408 (2016-02-10)
Hepatocellular carcinoma (HCC) is one of the most common cancers in Taiwan. Although chemotherapy is the primary treatment for HCC patients, drug resistance often leads to clinical failure. Galectin-1 is a beta-galactoside binding lectin which is up-regulated in HCC patients
Isabel Pablos et al.
Cell reports, 37(4), 109892-109892 (2021-10-22)
The main viral protease (3CLpro) is indispensable for SARS-CoV-2 replication. We delineate the human protein substrate landscape of 3CLpro by TAILS substrate-targeted N-terminomics. We identify more than 100 substrates in human lung and kidney cells supported by analyses of SARS-CoV-2-infected
Hilal Ahmad Parray et al.
International journal of molecular sciences, 16(7), 14441-14463 (2015-06-30)
Previously, galectin-1 (GAL1) was found to be up-regulated in obesity-prone subjects, suggesting that use of a GAL1 inhibitor could be a novel therapeutic approach for treatment of obesity. We evaluated thiodigalactoside (TDG) as a potent inhibitor of GAL1 and identified

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service